HC Wainwright Has Positive View of KALA BIO FY2025 Earnings

Key Points

• HC Wainwright has raised its FY2025 earnings per share (EPS) estimate for KALA BIO from ($5.96) to ($5.65), maintaining a "Buy" rating and a price target of $35.00.
• KALA BIO stock has seen significant volatility, with a 52-week range of $2.92 to $20.60, and currently trading at $17.53.
• In recent insider activity, Director Mark T. Iwicki sold 13,227 shares, indicating an 4.87% decrease in their ownership position.

KALA BIO, Inc. (NASDAQ:KALA - Free Report) - Research analysts at HC Wainwright upped their FY2025 EPS estimates for shares of KALA BIO in a research report issued on Wednesday, September 17th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($5.65) for the year, up from their previous estimate of ($5.96). HC Wainwright has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for KALA BIO's current full-year earnings is ($10.84) per share. HC Wainwright also issued estimates for KALA BIO's Q4 2025 earnings at ($1.12) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.60) EPS, Q3 2026 earnings at ($1.59) EPS, Q4 2026 earnings at ($1.39) EPS and FY2026 earnings at ($5.89) EPS.

KALA BIO (NASDAQ:KALA - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($1.71) EPS for the quarter, topping the consensus estimate of ($1.82) by $0.11.

Several other equities analysts also recently commented on KALA. Oppenheimer upped their price objective on shares of KALA BIO from $15.00 to $33.00 and gave the company an "outperform" rating in a research note on Thursday, September 11th. Lifesci Capital upgraded shares of KALA BIO to a "strong-buy" rating in a report on Wednesday, September 3rd. LADENBURG THALM/SH SH initiated coverage on shares of KALA BIO in a research report on Friday, July 11th. They set a "buy" rating and a $12.00 price objective on the stock. Wall Street Zen cut shares of KALA BIO from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, Mizuho began coverage on shares of KALA BIO in a research note on Monday, September 8th. They set an "outperform" rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $27.50.

KALA BIO Price Performance

Shares of KALA traded down $0.57 during mid-day trading on Friday, reaching $17.99. 84,196 shares of the stock traded hands, compared to its average volume of 113,836. KALA BIO has a 1 year low of $2.92 and a 1 year high of $20.60. The firm has a fifty day moving average price of $10.38 and a 200 day moving average price of $6.59. The company has a market cap of $126.25 million, a price-to-earnings ratio of -2.66 and a beta of -1.82. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 3.19.

Hedge Funds Weigh In On KALA BIO

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC lifted its holdings in KALA BIO by 35.7% in the 1st quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company's stock valued at $1,713,000 after purchasing an additional 78,582 shares in the last quarter. Readystate Asset Management LP acquired a new stake in shares of KALA BIO during the first quarter worth approximately $243,000. AIGH Capital Management LLC grew its position in shares of KALA BIO by 61.9% during the first quarter. AIGH Capital Management LLC now owns 196,350 shares of the company's stock worth $1,125,000 after buying an additional 75,048 shares in the last quarter. Woodline Partners LP bought a new position in KALA BIO during the first quarter worth $1,483,000. Finally, Geode Capital Management LLC lifted its stake in KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock valued at $268,000 after buying an additional 1,534 shares during the last quarter. 24.61% of the stock is owned by institutional investors and hedge funds.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.